Role of Insect-Derived Antimicrobial Peptides in Overcoming Multidrug-Resistant Infections

The rise of antibiotic resistance has emerged as a critical global health threat, necessitating the urgent development of novel antimicrobial agents. Insect-derived antimicrobial peptides (AMPs) offer a promising alternative to conventional antibiotics due to their broad-spectrum activity, rapid bactericidal mechanisms, and reduced likelihood of inducing resistance. Insects, which constitute the largest and most diverse group of organisms, have evolved a sophisticated innate immune system that produces AMPs to counteract microbial infections. These peptides exhibit diverse structures and mechanisms of action, including membrane disruption, inhibition of intracellular targets, and modulation of immune responses. Notable insect AMPs, such as defensins, cecropins, and drosocins, have demonstrated potent activity against multidrug-resistant (MDR) bacterial strains, including Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. This review explores the potential of insect-derived AMPs as next-generation therapeutics to combat antibiotic resistance. It examines their structural diversity, mechanisms of action, and efficacy against MDR pathogens. Furthermore, it discusses the challenges associated with their clinical application, including stability, toxicity, and large-scale production, along with recent advancements in synthetic modifications and nanotechnology-based delivery systems. By harnessing the antimicrobial potential of insect AMPs, researchers can develop innovative strategies to address the growing crisis of antibiotic resistance. This study highlights the necessity of integrating insect-derived AMPs into the antibiotic pipeline and emphasizes their role as a viable solution for the post-antibiotic era.